A Phase I Study of ABT-888 with Carboplatin and Paclitaxel in Patients with Solid Tumors Who Have Liver or Kidney Problems

Full Title
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors (NCI Protocol #8808)

Paclitaxel and carboplatin are two standard drugs commonly used to treat solid tumors. ABT-888 is an investigational drug that may prevent cancer cells from repairing the damage inflicted by chemotherapy drugs. The combination of ABT-888 with conventional anticancer drugs may make the chemotherapy work better.

People with liver or kidney problems may metabolize drugs differently than people with normal liver and kidney function. In this study, researchers want to find the best dose of ABT-888 that can be used in people with advanced solid tumors who have liver or kidney problems.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a metastatic or inoperable solid tumor that persists despite other treatment and is likely to respond to carboplatin/paclitaxel (such as breast, lung, or ovarian cancer or melanoma).
  • Patients must have impaired liver or kidney function, but may not have both. (A small group of people with solid tumors and normal liver and kidney function may also receive treatment for comparison purposes.)
  • At least 4 weeks must have passed since completion of prior chemotherapy or radiation therapy and entry into the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. David Spriggs at 646-888-4223.